EUCTR2008-002102-19-SE进行中（未招募）1 期
Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma - COMPARZ
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 927
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. This study remains open to allow subjects currently on treatment continued access to their treatment (as determined by the investigator). No new subjects will be entered.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 532
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 395
排除标准
- •Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. This study remains open to allow subjects currently on treatment continued access to their treatment (as determined by the investigator). No new subjects will be entered.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial comparing the effectiveness of pazopanib versus sunitinib in treating people with advanced kidney cancer.ocally Advanced and/or Metastatic Renal Cell CarcinomaMedDRA version: 19.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-002102-19-GBovartis Pharma Services AG927
进行中（未招募）
1 期
A Clinical Trial comparing the effectiveness of pazopanib versus sunitinib in treating people with advanced kidney cancer.ocally Advanced and/or Metastatic Renal Cell CarcinomaMedDRA version: 14.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-002102-19-IEGlaxoSmithKline Research & Development Ltd927
进行中（未招募）
1 期
Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinomaocally Advanced and/or Metastatic Renal Cell CarcinomaMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2008-002102-19-NLGlaxoSmithKline Research & Development Ltd876
进行中（未招募）
1 期
A clinical trial comparing the effectiveness of pazopanib versus sunitinib in treating people with advanced kidney cancer.EUCTR2008-002102-19-DEGlaxoSmithKline Research & Development Ltd927
已完成
3 期
A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinomaocally Advanced and/or Metastatic Renal Cell CarcinomaLocally Advanced and/or Metastatic Renal Cell CarcinomaCancer - KidneyACTRN12609000392268GlaxoSmithKline876